Bambusa Therapeutics Inc. (BBTX:NASDAQ) closed at $16.00 on November 20, 2026, up 2.89% on the day. The stock trades 9.3% below its 52-week high of $17.65 and 17.6% above its 52-week low of $13.60. Over the past year, it gained 6.7%. Bambusa Therapeutics Inc. is part of the Health Care sector.
Bambusa Therapeutics is a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation and fundamentally improve patient quality of life. The company combines third-party, advanced antibody engineering and clinically and commercially validated biologic pathways into a single molecule formulated for high-concentration subcutaneous delivery to improve durability, convenience, and clinical differentiation beyond the current capabilities of existing monotherapies. Its pipeline includes BBT001, a bispecific antibody targeting IL-4R¿ and IL-31, in clinical development for atopic dermatitis and other inflammatory skin diseases; BBT002, a bispecific antibody targeting IL-4R¿ and IL-5 in clinical development for Type 2 inflammatory disorders; and preclinical programs BBT003 and BBT004 focused on gastroenterology and autoantibody-driven autoimmune diseases, respectively.
Find more stocks like BBTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.